Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC-MPS (Ruiyirong) after living donor kidney transplantation
ChiCTR2600121665Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mycophenolate sodium in end-stage kidney disease (ESKD), kidney transplant and kidney allograft rejection, sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Incidence of acute rejection within 6 months post-surgery and Renal function parameters. Started Apr 2026; status: recruiting.
02
Drugs
mycophenolate sodium
03
Conditions
end-stage kidney disease (ESKD)kidney transplantkidney allograft rejection
Beyond the preview
Go deeper on ChiCTR2600121665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121665.